Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Autor: Yusuke Seino, Eri Wada, Masahiko Ando, Mariko Furukawa, Norio Okada, Ryoichi Banno, Daisuke Hagiwara, Hiroshi Takagi, Shintaro Iwama, Taku Tsunekawa, Takayuki Okuji, Yoshiaki Morishita, Hiroshi Arima, Tomoko Kobayashi, Hidetaka Suga, Mariko Sugiyama, Motomitsu Goto, Yoji Hamada, Takeshi Onoue, Yoshihiro Ito, Etsuko Yamamori
Rok vydání: 2019
Předmět:
Male
Apolipoprotein B
Blood Pressure
Dipeptidyl peptidase-4 inhibitor
Type 2 diabetes
030204 cardiovascular system & hematology
Biochemistry
Vascular Medicine
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Medicine and Health Sciences
Hypolipidemic Agents
Multidisciplinary
biology
Fasting
Middle Aged
Lipids
Lipid Profiles
Type 2 Diabetes
Cholesterol
Anagliptin
Medicine
lipids (amino acids
peptides
and proteins)
Female
Adiponectin
Anatomy
medicine.drug
Research Article
medicine.medical_specialty
Endocrine Disorders
Science
Lipoproteins
030209 endocrinology & metabolism
03 medical and health sciences
Diabetes mellitus
Internal medicine
medicine
Diabetes Mellitus
Humans
Triglycerides
Aged
Dyslipidemias
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
business.industry
Cholesterol
HDL
Biology and Life Sciences
Proteins
Lipid metabolism
Cholesterol
LDL
medicine.disease
Lipid Metabolism
Gastrointestinal Tract
Pyrimidines
Metabolism
Apolipoproteins
chemistry
Diabetes Mellitus
Type 2
Metabolic Disorders
biology.protein
Glycated hemoglobin
business
Apolipoprotein B-48
Digestive System
Zdroj: PLoS ONE
PLoS ONE, Vol 15, Iss 1, p e0228004 (2020)
ISSN: 1932-6203
Popis: Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications. Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. This study aimed to conduct an investigation into the effects of anagliptin on serum lipid profiles. This multicenter, open-label, randomized (1:1), parallel group study was designed to evaluate the effects of anagliptin on serum lipid profiles (triglycerides, lipoproteins, apolipoproteins, and cholesterol fractions). The study involved 24 patients with type 2 diabetes at two participating hospitals for a period of 24 weeks. Patients were randomly assigned to the anagliptin (n = 12) or control (n = 12) groups. Patients in the anagliptin group were treated with 200 mg of the drug twice daily. Patients in the control group did not receive anagliptin, but continued with their previous treatment schedules. Lipid metabolism was examined under fasting conditions at baseline and 24 weeks. Patients treated with anagliptin for 24 weeks exhibited significantly reduced levels of serum apolipoprotein B-48, a marker for lipid transport from the intestine, compared with the control group patients (P < 0.05). After 24 weeks of treatment, serum adiponectin levels were significantly raised, whereas glycated hemoglobin (HbA1c) levels were significantly lower compared with the baseline in the anagliptin group (P < 0.05), but not in the control group. This study showed that the DPP-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels, suggesting that this drug may have beneficial effects on lipid metabolism possibly mediated by the inhibition of intestinal lipid transport.
Databáze: OpenAIRE
Externí odkaz: